Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Effect of ACAT inhibition on the progression of coronary atherosclerosis.

Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM; ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators.

N Engl J Med. 2006 Mar 23;354(12):1253-63. Erratum in: N Engl J Med. 2006 Aug 10;355(6):638.

2.

Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study.

Nicholls SJ, Sipahi I, Schoenhagen P, Wisniewski L, Churchill T, Crowe T, Goormastic M, Wolski K, Tuzcu EM, Nissen SE; ACTIVATE Investigators.

Am Heart J. 2006 Jul;152(1):67-74.

PMID:
16824833
3.

ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.

Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, Davidson MH, Zwinderman AH, Schwocho LR, Stein EA; CAPTIVATE Investigators.

JAMA. 2009 Mar 18;301(11):1131-9. doi: 10.1001/jama.301.11.1131.

PMID:
19293413
4.

Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.

Tardif JC, Grégoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, McLain R, Pressler ML, Ibrahim R, Lespérance J, Blue J, Heinonen T, Rodés-Cabau J; Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators.

Circulation. 2004 Nov 23;110(21):3372-7. Epub 2004 Nov 8.

5.

Failure of ACAT inhibition to retard atherosclerosis.

Fazio S, Linton M.

N Engl J Med. 2006 Mar 23;354(12):1307-9. No abstract available.

PMID:
16554534
6.

Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.

Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE.

JAMA. 2013 Sep 18;310(11):1135-44. doi: 10.1001/jama.2013.277169.

PMID:
23999933
7.

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators.

JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1.

PMID:
18387931
8.

Effect of torcetrapib on the progression of coronary atherosclerosis.

Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators.

N Engl J Med. 2007 Mar 29;356(13):1304-16. Epub 2007 Mar 26. Erratum in: N Engl J Med. 2007 Aug 23;357(8):835. Lasala, Gregory P [corrected to Lasala, Gabriel P].

9.

Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials.

Sipahi I, Tuzcu EM, Wolski KE, Nicholls SJ, Schoenhagen P, Hu B, Balog C, Shishehbor M, Magyar WA, Crowe TD, Kapadia S, Nissen SE.

Ann Intern Med. 2007 Jul 3;147(1):10-8.

PMID:
17606956
10.

ACAT inhibition and the progression of coronary atherosclerosis.

Rudel LL, Farese RV Jr.

N Engl J Med. 2006 Jun 15;354(24):2616-7; author reply 2616-7. No abstract available.

11.

Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression.

Berry C, L'Allier PL, Grégoire J, Lespérance J, Levesque S, Ibrahim R, Tardif JC.

Circulation. 2007 Apr 10;115(14):1851-7. Epub 2007 Mar 26.

12.

Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial.

Tardif JC, Grégoire J, Lespérance J, Lambert J, L'Allier PL, Rodés J, Anderson T, Blue JW, Imus J, Heinonen T.

Am Heart J. 2002 Oct;144(4):589-96.

PMID:
12360153
13.

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators.

JAMA. 2007 Apr 18;297(15):1675-82. Epub 2007 Mar 26.

PMID:
17387133
14.

Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits.

Kitayama K, Koga T, Maeda N, Inaba T, Fujioka T.

Eur J Pharmacol. 2006 Jun 6;539(1-2):81-8. Epub 2006 Apr 7.

PMID:
16690054
15.

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R.

JAMA. 2003 Nov 5;290(17):2292-300.

PMID:
14600188
16.

Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.

Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE.

JAMA. 2007 Feb 7;297(5):499-508.

PMID:
17284700
17.

Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.

Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW; APPROACH Study Group.

Circulation. 2010 Mar 16;121(10):1176-87. doi: 10.1161/CIRCULATIONAHA.109.881003. Epub 2010 Mar 1.

18.

[New agents against atherosclerosis tested. Alarming findings, ACAT inhibitors seem to have proatherogenic effects].

Wiklund O.

Lakartidningen. 2006 Oct 25-31;103(43):3270. Swedish. No abstract available.

PMID:
17117657
19.

ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.

Terasaka N, Miyazaki A, Kasanuki N, Ito K, Ubukata N, Koieyama T, Kitayama K, Tanimoto T, Maeda N, Inaba T.

Atherosclerosis. 2007 Feb;190(2):239-47. Epub 2006 Apr 19.

PMID:
16626720
20.

Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.

Kitayama K, Tanimoto T, Koga T, Terasaka N, Fujioka T, Inaba T.

Eur J Pharmacol. 2006 Jul 1;540(1-3):121-30. Epub 2006 Apr 29.

PMID:
16730694

Supplemental Content

Support Center